{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:38:59Z","timestamp":1789468739442,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","techvir.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Techniques in Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.tvir.2024.100958","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T12:03:52Z","timestamp":1719662632000},"page":"100958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulation in Pediatric Patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Marilyn J.","family":"Manco-Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Annam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Schardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tvir.2024.100958_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/00006450-199401000-00016","article-title":"Heparin therapy in pediatric patients: a prospective cohort study","volume":"35","author":"Andrew","year":"1994","journal-title":"Pediatr Res"},{"key":"10.1016\/j.tvir.2024.100958_bib0002","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","article-title":"Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients","volume":"94","author":"Streif","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.tvir.2024.100958_bib0003","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0022-3476(96)70273-1","article-title":"Low-molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study","volume":"128","author":"Massicotte","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.tvir.2024.100958_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2004-11-4211","article-title":"How I treat venous thrombosis in children","volume":"107","author":"Manco-Johnson","year":"2006","journal-title":"Blood"},{"issue":"23 Suppl1","key":"10.1016\/j.tvir.2024.100958_bib0005","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tvir.2024.100958_bib0006","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.tvir.2024.100958_bib0007","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants\u2019 data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.tvir.2024.100958_bib0008","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-2796.2000.00662.x","article-title":"The DURAC trial study group. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg","volume":"247","author":"Lindmarker","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.tvir.2024.100958_bib0009","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tvir.2024.100958_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the kids-DOTT randomized clinical trial","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA."},{"issue":"19","key":"10.1016\/j.tvir.2024.100958_bib0011","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1182\/bloodadvances.2020002637","article-title":"Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)","volume":"4","author":"Thom","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.tvir.2024.100958_bib0012","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.tvir.2024.100958_bib0013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcph.1716","article-title":"Population pharmacokinetic analysis of dalteparin in pediatric patients with venous thromboembolism","volume":"61","author":"Damle","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.tvir.2024.100958_bib0014","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pbc.22852","article-title":"Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy and pharmacokinetic study","volume":"56","author":"Young","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.tvir.2024.100958_bib0015","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/jth.13057","article-title":"UNBLOCK; an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis","volume":"13","author":"O'Brien","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12959-018-0185-1","article-title":"Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN Jr phase 1 study","volume":"16","author":"Willmann","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.tvir.2024.100958_bib0017","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/psp4.12935","article-title":"Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder","volume":"12","author":"Mirali","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.tvir.2024.100958_bib0018","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"DIVERSITY trial investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tvir.2024.100958_bib0019","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0040-1715460","article-title":"The anticoagulant and nonanticoagulant properties of heparin","volume":"120","author":"Beurskens","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0020","first-page":"2153","article-title":"Clinical pharmacology of direct and indirect factor Xa inhibitors","volume":"70","author":"Rupprecht","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.tvir.2024.100958_bib0021","first-page":"507151","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Mousavi","year":"2015","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.tvir.2024.100958_bib0022","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Brit J Clin Pharmacol"},{"key":"10.1016\/j.tvir.2024.100958_bib0023","article-title":"Oral direct thrombin inhibitors or oral direct factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis (Review)","volume":"V4","author":"Wang","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tvir.2024.100958_bib0024","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"Interactions of warfarin with drugs and food","volume":"121","author":"Wells","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tvir.2024.100958_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.tvir.2024.100958_bib0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.tvir.2024.100958_bib0027","first-page":"408","article-title":"Bivalirudin as an alternative to heparin for anticoagulation in infants and children","volume":"20","author":"Buck","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.tvir.2024.100958_bib0028","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"CHEST"},{"key":"10.1016\/j.tvir.2024.100958_bib0029","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tvir.2024.100958_bib0030","article-title":"Antiphospholipid syndrome. Advances in diagnosis, pathogenesis and management","volume":"380","author":"Knight","year":"2023","journal-title":"Brit Med J"},{"key":"10.1016\/j.tvir.2024.100958_bib0031","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-020-00901-y","article-title":"New insights into the use of direct oral anticoagulants in non-high risk thrombotic APS patients: literature review and subgroup analysis from a meta-analysis","volume":"22","author":"Dufrost","year":"2020","journal-title":"Curr Rheum Reports"},{"key":"10.1016\/j.tvir.2024.100958_bib0032","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tvir.2024.100958_bib0033","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqac131","article-title":"Monitoring direct thrombin inhibitors with calibrated diluted thrombin time vs activated partial thromboplastin time in pediatric patients. Rida A","volume":"159","author":"Hasan","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tvir.2024.100958_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. A systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.tvir.2024.100958_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0042-1760332","article-title":"Hemostasis in the pregnant woman, the placenta, the fetus and the newborn infant","volume":"49","author":"Warren","year":"2023","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2019.02.025","article-title":"Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life","volume":"177","author":"Heizer","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.tvir.2024.100958_bib0037","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1538-7836.2012.04624.x","article-title":"Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels","volume":"10","author":"Schechter","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2010.03672.x","article-title":"Warfarin and vitamin K intake in the era of pharmacogenetics","volume":"70","author":"Lurie","year":"2010","journal-title":"Brit J Clin Pharmacol"},{"key":"10.1016\/j.tvir.2024.100958_bib0039","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/hematology.2020000138","article-title":"Management of heavy menstrual bleeding on anticoagulation","volume":"1","author":"Bannow","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.tvir.2024.100958_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.932085","article-title":"Adverse events of DOACs in children","volume":"10","author":"Bosch","year":"2022","journal-title":"Frontiers in Pediatr"},{"issue":"2 Suppl","key":"10.1016\/j.tvir.2024.100958_bib0041","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.tvir.2024.100958_bib0042","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00043426-200003000-00011","article-title":"Low-molecular-weight heparin in thrombotic disease in children and adolescents","volume":"22","author":"Punzalan","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.tvir.2024.100958_bib0043","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2010.08163.x","article-title":"Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children","volume":"149","author":"Ignjatovic","year":"2010","journal-title":"BJH"},{"issue":"4","key":"10.1016\/j.tvir.2024.100958_bib0044","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1345\/aph.1D107","article-title":"Anti-Xa stability of diluted enoxaparin for use in pediatrics","volume":"38","author":"Dager","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.tvir.2024.100958_bib0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin","volume":"99","author":"Warkentin","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.860369","article-title":"Practical considerations for use of direct acting oral anticoagulants in children","volume":"10","author":"Whitworth","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.tvir.2024.100958_bib0047","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jtha.2023.03.005","article-title":"Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease","volume":"21","author":"VanderPluym","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0048","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tvir.2024.100958_bib0049","unstructured":"Dabigatran dosing: https:\/\/reference.medscape.com\/drug\/pradaxa-dabigatran-342135. Accessed July 19, 2024."},{"key":"10.1016\/j.tvir.2024.100958_bib0050","first-page":"395","article-title":"Homozygous protein C deficiency; early treatment with warfarin","volume":"11","author":"Hartman","year":"1989","journal-title":"Amer J Pediatr Hematol Oncol"},{"key":"10.1016\/j.tvir.2024.100958_bib0051","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","article-title":"Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients","volume":"94","author":"Streif","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.tvir.2024.100958_bib0052","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.107.715821","article-title":"Clopidogrel: dosing of clopidogrel for platelet inhibition in infants and young children on cLOpidogrel (PICOLO) trial","volume":"117","author":"Li","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.tvir.2024.100958_bib0053","unstructured":"Clopidogrel: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020839s048lbl.pdf. Accessed July 19, 2024."},{"issue":"5","key":"10.1016\/j.tvir.2024.100958_bib0054","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jpeds.2005.05.006","article-title":"Clopidogrel use in children","volume":"147","author":"Finkelstein","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.tvir.2024.100958_bib0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2018.07.013","article-title":"Treatment of arterial thrombosis in children: methods and mechanisms","volume":"169","author":"Rizzi","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.tvir.2024.100958_bib0056","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1161\/STR.0000000000000183","article-title":"Management of stroke in neonates and children: a scientific statement from the American heart association\/American stroke association","volume":"50","author":"Ferriero","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.tvir.2024.100958_bib0057","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0032-1302450","article-title":"Deep vein thrombosis. Thrombolysis in the pediatric population","volume":"29","author":"Greene","year":"2012","journal-title":"Semin Interv Radiol"},{"key":"10.1016\/j.tvir.2024.100958_bib0058","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jvir.2010.10.013","article-title":"Percutaneous mechanical and pharmacomechanical thrombolysis of occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric thromboembolism","volume":"22","author":"Goldenberg","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.tvir.2024.100958_bib0059","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fped.2017.00260","article-title":"Pediatric thrombolysis: a practical approach","volume":"5","author":"Tarango","year":"2017","journal-title":"Front Pediatr"},{"key":"10.1016\/j.tvir.2024.100958_bib0060","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jvir.2015.12.753","article-title":"Endovascular thrombolysis in the management of iliofemoral thrombosis in children: a multi-insitutional experience","volume":"27","author":"Gaballah","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.tvir.2024.100958_bib0061","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"JCI"},{"issue":"3","key":"10.1016\/j.tvir.2024.100958_bib0062","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.chest.2021.09.019","article-title":"Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review","volume":"161","author":"Ross","year":"2022","journal-title":"Chest"}],"container-title":["Techniques in Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089251624000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089251624000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:18:54Z","timestamp":1724051934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089251624000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1089251624000143"],"URL":"https:\/\/doi.org\/10.1016\/j.tvir.2024.100958","relation":{},"ISSN":["1089-2516"],"issn-type":[{"value":"1089-2516","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in Pediatric Patients","name":"articletitle","label":"Article Title"},{"value":"Techniques in Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvir.2024.100958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100958"}}